Bluejay Diagnostics Executes 1-for-4 Reverse Stock Split to Boost Share Price

Event summary

  • Bluejay Diagnostics approved a 1-for-4 reverse stock split, effective January 29, 2026.
  • Outstanding shares reduced from ~2.83 million to ~708,533, with no fractional shares issued.
  • Trading continues under the same ticker (BJDX) but with a new CUSIP number (095633608).
  • Company’s Symphony System awaits FDA clearance for its sepsis diagnostic product.

The big picture

Bluejay’s reverse stock split is a strategic move to enhance liquidity and attract investors, but its long-term success hinges on securing FDA approval for its Symphony System. The medical diagnostics sector is increasingly competitive, with rapid, near-patient testing solutions gaining traction in critical care settings. Bluejay’s ability to navigate regulatory hurdles and scale its technology will determine its market positioning.

What we're watching

Regulatory Timing
How quickly Bluejay secures FDA clearance for its Symphony System, which is critical for commercialization.
Market Reaction
Whether the reverse stock split stabilizes or boosts Bluejay’s share price amid broader market conditions.
Operational Milestones
The pace at which Bluejay advances its IL-6 Test and other product candidates toward market readiness.